GeneDx Q3 2025 Earnings Release

GeneDx Holdings Corp. reported its financial results for the third quarter of 2025, showcasing significant growth. The company achieved revenues of $116.7 million, a 52% increase year-over-year, with exome and genome test revenue growing by 65% to $98.9 million. Adjusted gross margin expanded to 74%, up from 64% in the same quarter of the previous year. GeneDx also generated an adjusted net income of $14.7 million for the quarter. The company raised its full-year revenue guidance to between $425 and $428 million, reflecting confidence in its growth trajectory. Key business highlights include the FDA Breakthrough Device Designation for GeneDx ExomeDx™ and GenomeDx™, and participation in significant genomic newborn screening initiatives.